Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11584933 RNA interference in ocular indications

Patent 11584933 was granted and assigned to Phio Pharmaceuticals Corp. on February, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Patent Applicant

Phio Pharmaceuticals Corp.

Current Assignee

Phio Pharmaceuticals Corp.

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Date of Patent

February 21, 2023

Patent Application Number

15930377

Date Filed

May 12, 2020

Patent Citations

US Patent 10240149 Reduced size self-delivering RNAi compounds

US Patent 10300027 Effective sensitizing dose of a gelled immunomodulating topical composition

US Patent 10479992 RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality

US Patent 10633654 Modified RNAi polynucleotides and uses thereof

US Patent 10662430 RNA interference in ocular indications

US Patent 10774330 Reduced size self-delivering RNAI compounds

US Patent 10808247 Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach

US Patent 10815485 RNA interference in skin indications

...

Patent Citations Received

US Patent 11926828 Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1

0

Patent Primary Examiner

CPC Code

The present invention relates to ocular administration of sd-rxRNA and rxRNAori molecules.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11584933 RNA interference in ocular indications

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.